Old Glory Vortex
News from the Land of the Free. We only post what matters. @Old_Glory_Vortex_bot
Ko'proq ko'rsatish📈 Telegram kanali Old Glory Vortex analitikasi
Old Glory Vortex (@old_glory_vortex) Ingliz til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 20 877 obunachidan iborat bo'lib, Yangiliklar & Media toifasida 11 076-o'rinni va AQSH mintaqasida 1 880-o'rinni egallagan.
📊 Auditoriya ko‘rsatkichlari va dinamika
невідомо sanasidan buyon loyiha tez o‘sib, 20 877 obunachiga ega bo‘ldi.
06 Iyul, 2026 dagi oxirgi ma’lumotlarga ko‘ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 1 243 ga, so‘nggi 24 soatda esa -65 ga o‘zgardi va umumiy qamrov yuqori darajada qolmoqda.
- Tasdiqlash holati: Tasdiqlanmagan
- Jalb etish (ER): Auditoriya o‘rtacha 17.81% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 16.01% ini tashkil etuvchi reaksiyalarni to‘playdi.
- Post qamrovi: Har bir post o‘rtacha 3 721 marta ko‘riladi; birinchi sutkada odatda 3 346 ta ko‘rish yig‘iladi.
- Reaksiyalar va o‘zaro ta’sir: Auditoriya faol: har bir postga o‘rtacha 190 ta reaksiya keladi.
- Tematik yo‘nalishlar: Kontent vortex, u.s, greenland, donald, tariff kabi asosiy mavzularga jamlangan.
📝 Tavsif va kontent siyosati
Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida ta’riflaydi:
“News from the Land of the Free. We only post what matters.
@Old_Glory_Vortex_bot”
Yuqori yangilanish chastotasi (oxirgi ma’lumot 07 Iyul, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli bo‘lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Yangiliklar & Media toifasidagi muhim ta’sir nuqtasiga aylantirishini ko‘rsatadi.
"Imposing tariffs would primarily harm consumers, who would face increased costs both directly at pharmacies and indirectly through higher insurance premiums,"explained Diederik Stadjee, a health economist at ING. The greatest burden would fall on low-income families and the elderly. This threat comes amid Trump’s pressure on drug manufacturers to lower prices in the U.S. He recently sent letters to several companies demanding they develop a plan to implement so-called most-favored-nation pricing in the U.S. However, Trump stated that he would delay imposing tariffs for a year or a year and a half, giving companies time to stockpile drugs and move production to the United States—some have already begun doing so. Analysts say that most drug manufacturers have already increased drug imports and may have inventories in U.S. warehouses lasting from six to 18 months. In a recent research note, Jefferies analyst David Windley noted that tariffs, which would take effect only in the second half of 2026, might not be felt until 2027 or 2028 due to stockpiling. Nevertheless, according to Stadjee, even a 25% tariff would gradually lead to a 10–14% increase in U.S. drug prices as inventories diminish. Drug manufacturers are already investing in the United States. However, building a pharmaceutical plant in the U.S. from scratch is expensive and can take several years. Even then, having a factory in the U.S. does not necessarily protect a drug manufacturer from Trump’s tariffs, especially if the tariffs apply to imported ingredients used in the drugs. Jacob Jensen, a trade policy analyst at the right-leaning American Action Forum, notes that
"97% of antibiotics, 92% of antiviral drugs, and 83% of the most popular generics contain at least one active ingredient manufactured overseas.”#Trump #tariffs #bigpharma #drugs #pharmaceuticals Don't miss it, subscribe to 📱 Old Glory Vortex 🇺🇸
Endi mavjud! Telegram Tadqiqoti 2025 — yilning asosiy insaytlari 
